Skip Navigation



European Heart Journal Advance Access published online on August 1, 2008
European Heart Journal, doi:10.1093/eurheartj/ehn348
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
29/17/2061    most recent
ehn348v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Herrler, T.
Right arrow Articles by Heeschen, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Herrler, T.
Right arrow Articles by Heeschen, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org

More good reasons for adherence to statin therapy during acute coronary syndromes

Tanja Herrler1, Michael Böhm2 and Christopher Heeschen1,*

1 Department of Experimental Medicine, Ludwig Maximilian University, Marchioninistr. 15, 81377 Munich, Germany
2 Department for Internal Medicine III, University of the Saarland, Homburg, Germany

* Corresponding author. Tel: +49 89 7095 3438, Fax: +49 89 7095 6433, Email: christopher.heeschen@med.uni-muenchen.de

This editorial refers to ‘Discontinuation of statin therapy following an acute myocardial infarction: a population-based study,’ by S.D. Daskalopoulo et al. doi:10.1093/eurheartj/ehn346

The first 10% of the full text of this article appears below.

During the last decade, the evidence that statins have potent effects in reducing death and myocardial infarction in patients following acute coronary syndromes has become overwhelming, both in patients with elevated cholesterol levels and in those with normal cholesterol levels.1,2 Beyond their intended impact on blood cholesterol levels, statins are also known to have multiple non-lipid effects that contribute to the reduction of cardiovascular morbidity and mortality.3,4 Statins may prevent acute thrombus formation at the site of plaque rupture by inhibiting platelet function and inhibiting platelet deposition on damaged vessels. They have also been shown to contribute to plaque stabilization, not only through a reduction in lipids but also as a result of reduced macrophage accumulation in atherosclerotic lesions and inhibition of expression of matrix metalloproteinases. Statins have anti-inflammatory properties; they reduce levels of high sensitivity C-reactive protein and, through attenuation . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Discontinuation of statin therapy following an acute myocardial infarction: a population-based study
Stella S. Daskalopoulou, Joseph A.C. Delaney, Kristian B. Filion, James M. Brophy, Nancy E. Mayo, and Samy Suissa
EHJ 2008 29: 2083-2091. [Abstract] [FREE Full Text]